Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism

Clinical Pharmacokinetics

Volumn 31, Issue 3, 1996, Pages 215-230

  Pirmohamed, Munir ^a   Madden, Stephen ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANESTHETIC AGENT; CARBAMAZEPINE; CIMETIDINE; CITALOPRAM; COTRIMOXAZOLE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DAPSONE; DIAZEPAM; DRUG METABOLIZING ENZYME; ENFLURANE; EPOXIDE HYDROLASE; FLUTAMIDE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROXYLAMINE; IMIPRAMINE; ISOFLURANE; METHOXYFLURANE; MICROSOME ENZYME; MIXED FUNCTION OXIDASE; MYELOPEROXIDASE; OMEPRAZOLE; PARACETAMOL; PROGUANIL; PROPRANOLOL DERIVATIVE; PROSTAGLANDIN SYNTHASE; TACRINE; TIENILIC ACID; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALCOHOL METABOLISM; BIOTRANSFORMATION; BLOOD TOXICITY; DRUG ACTIVATION; DRUG METABOLISM; DRUG TOXICITY; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER NECROSIS; LIVER TOXICITY; METABOLIC ACTIVATION; METHEMOGLOBINEMIA; NEPHROTOXICITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; REVIEW;

EID: 10144260620     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631030-00005     Document Type: Review

References (152)

1. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editors. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977: 44
2. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95
3. Park BK, Kitteringham NR. Adverse drug reactions and drug metabolism. Adverse Drug React Bull 1987; 122: 456-9
4. Woolf TF, Jordan RA. Basic concepts in drug metabolism: part 1. J Clin Pharmacol 1987; 27: 15-7
5. Tephly TR, Burchell B. UDP-glucuronyl transferases: a family of detoxifying enzymes. Trends Pharmacol Sci 1990; 11: 276-29
6. Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf 1994; 11: 114-44
7. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995; 68: 385-424
8. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992; 54: 17-61
9. Juchau MR, Lee QP, Fantel AG. Xenobiotic biotransformation/bioactivation in organogenesis-stage conceptal issues: implications for embryotoxicity and teratogenesis. Drug Metab Rev 1992; 24: 195-238
10. Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987; 36: 581-90
11. Pohl LR, Satoh H, Christ DD, et al. Immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol 1988; 28: 367-87
12. Gillette JR, Lau SS, Monks TJ. Intra-and extra-cellular formation of metabolites from chemically reactive species. Biochem Soc Trans 1984; 12: 4-7
13. Boelsterli UA. Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab Rev 1993; 25: 395-451
14. Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol 1988; 2: 385-423
15. Gonzalez FJ, Jaiswal AK, Nebert DW. P450 genes: evolution, regulation, and relationship to human cancer and pharmacogenetics. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 2: 879-90
16. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 243-88
17. Forrester LM, Henderson CJ, Glancey MJ, et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs. Biochem J 1992; 281: 359-68
18. Nebert DW, Nelson DR, Adesnik M, et al. The P450 gene superfamily. Update on the naming of new genes and nomenclature of chromosomal loci. DNA 1989; 8: 1-13
19. Nebert DW, Nelson DR, Coon MJ, et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1-14
20. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update of new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42
21. Murray BP, Edwards RJ, Murray S, et al. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 1993; 14: 585-92
22. Wong TK, Domin BA, Bent PE, et al. Correlation of placental microsomal activities with protein detected by antibodies to rabbit cytochrome-p-450 isozyme-6 in preparations from humans exposed to polychlorinated-biphenyls, quaterphenyls, and dibenzofurans. Cancer Res 1986; 46: 999-1004
23. Shimada T, Yun CH, Yamazaki H, et al. Characterization of human lung microsomal cytochrome-p-450 1a1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992; 41: 856-64
24. Crofts F, Cosma GN, Currie D, et al. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 1993; 14: 1729-31
25. Nakachi K, Imai K, Hayashi S, et al. Polymorphisms of the CYP1A1 and glutathione-s-transferase genes associated with susceptibility to lung-cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993; 53: 2994-9
26. Kudlubar FF. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 1994; 26: 37-46
27. Nakujima M, Yokoi T, Mizutani M, et al. Phenotyping of CYP1A2 in japanese population by analysis of caffeine urinary metabolites - absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994; 3: 413-21
28. Edwards RJ, Murray BP, Murray S, et al. Contribution of CYP1A1, and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 1994; 15: 829-36
29. Park BK, Madden S, Spaldin V, et al. Tacrine transaminitis: potential mechanisms. Alz Dis Assoc Disord 1994; 8: S39-49
30. Woolf TF, Pool WF, Walker RM, et al. Liver reactions to tacrine. In: Cameron RG, Feuer G, de la Iglesia FA, editors. Drug-induced hepatotoxicity. Berlin: Springer-Verlag, 1996: 395-410
31. Madden S, Woolf TF, Pool WF, et al. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: studies with human and rat liver microsomes. Biochem Pharmacol 1993; 46: 13-20
32. Spaldin V, Madden S, Pool WF, et al. The effect of enzyme-inhibition on the metabolism and activation of tacrine by human liver-microsomes. Br J Clin Pharmacol 1994; 38: 15-22
33. Spaldin V, Madden S, Adams DA, et al. Determination of human hepatic cytochrome P4501A2 activity in-vitro: use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995; 23: 929-34
34. Madden S, Spaldin V, Hayes RN, et al. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995; 25: 103-16
35. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28: 449-57
36. Dahl M-L, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71-4
37. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272: 984-90
38. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346-52
39. Goldstein JA, de Murais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-300
40. Page MA, Boutagy JS, Shenfield GM. A screening test for slow metabolizers of tolbutamide. Br J Clin Pharmacol 1991; 31: 649-54
41. Dansette PM, Amar C, Valadon P, et al. Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Biochem Pharmacol 1991; 41: 553-60
42. Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984; 55: 561-70
43. Beaune PH, Bourdi M. Autoantibodies against cytochrome P-450 in drug-induced autoimmune hepatitis. Ann NY Acad Sci 1993; 685: 641-5
44. Beaune P, Dansette PM, Mansuy D, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-5
45. Mansuy D, Valadon P, Erdelmeier I, et al. Thiophene S-oxides as new reactive metabolites: formation by cytochrome P450 dependent oxidation and reaction with nucleophiles. J Am Chem Soc 1991; 113: 7825-6
46. Smith GH. Treatment of infections in the patient with acquired immunodeficiency syndrome. Arch Intern Med 1994; 154: 949-73
47. Koopmans PP, Vanderven AJAM, Vree TB, et al. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV-infection: allergic or toxic. AIDS 1995; 9: 217-22
48. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5: 1237-57
49. van der Ven AJ, Koopmans PP, Vree TB, et al. Adverse reactions to co-trimoxazole in HIV infection. Lancet 1991; II: 431-3
50. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxlation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23: 406-14
51. Heril M, Jugert F, Merk HF. CD8(+) dermal t-cells from a sulfamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver-microsomes. Br J Dermatol 1995; 132: 215-20
52. Carr A, Vasak E, Munro V, et al. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV-infection. Clin Exp Immunol 1994; 97: 260-5
53. Carr A, Tindall B, Penny R, et al. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993; 94: 21-5
54. Rieder MJ, Uetrecht JP, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro 'rechallenge' with hydroxylamine metabolites. Ann Intern Med 1989; 110: 286-9
55. Vanderven AJM, Koopmans PP, Vree TB, et al. Drug intolerance in HIV disease. J Antimicrob Chemother 1994; 34: 15
56. Roederer M, Staal FJT, Osada H, et al. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int Immunol 1991; 3: 933-7
57. Buhl R, Holroyd KJ, Mastrangeli A, et al. Systemic glulathione deficiency in symptom-tree HIV-seropositive individuals. Lancet 1989; 11: 1294-8
58. Pirmohamed M, Williams D, Tingle MD, et al. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS 1996; 10: 501-7
59. Aukrust P, Svardal AM, Millier F, et al. Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type I infection. Blood 1995; 86: 258-67
60. Riley RJ, Cribb AE, Spielberg SP. Glutathione transferase a deficiency is not a marker for predisposition to sulphonamide toxicity. Biochem Pharmacol 1991; 42: 696-8
61. Coleman MD, Scott AK, Breckenridge AM, et al. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 1990; 30: 761-7
62. Rhodes LE, Tingle MD, Park BK, et al. Cimetidine improves the therapeutic toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995; 132: 257-62
63. Gonzalez F, Meyer UA. Molecular genetics of the debrisoquinsparteine polymorphism. Clin Pharmacol Ther 1991; 50: 233-8
64. Daly AK, Cholerton S, Gregory W, et al. Metabolic polymorphisms. Pharmacol Ther 1993; 57: 129-60
65. Koymans LMH, Donne-Op den Kelder GM, Koppele TE, et al. Cytochromes P450: their active-site structure and mechanism of oxidation. Drug Metab Rev 1993; 25: 325-87
66. Penman BW, Recce J, Smith T, et al. Characterization of a human cell-line expressing high-levels of CDNA-derived CYP2D6. Pharmacogenetics 1993; 3: 28-19
67. Guengerich FP, Turvy CG. Comparison of levels of several human cytochrome P450 microsomal enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1990; 256: 1189-94
68. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem Tokyo 1991; 110: 559-65
69. Day CP, Bassendine MF. Genetic predisposition to alcoholic liver disease. Gut 1992; 33: 1444-7
70. Tuma DJ, Klassen LW. Immune responses to acetaldehyde-protein adducts: role in alcoholic liver disease. Gastroenterology 1992; 103: 1969-73
71. Moncada C, Torres V, Varghese G, et al. Ethanol-derived immunoreactive species formed by free radical mechanisms. Mol Pharmacol 1994; 46: 786-91
72. Clot P, Bellomo G, Tabone M, et al. Detection of antibodies against proteins modified by hydroxyethyl free-radicals in patients with alcoholic cirrhosis. Gastroenterology 1995; 108: 201-7
73. Pirmohamed M, Kitteringham NR, Quest LJ, et al. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics 1995; 5: 351-7
74. Tsutsumi M, Takada A, Wang JS. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver-disease. Gastroenterology 1994; 107: 1430-5
75. Carr LG, Hartleroad JY, Liang YB, et al. Polymorphism at the P450IIE1 locus is anot associated with alcoholic liver disease in caucasian men. Alcohol Clin Exp Res 1994; 19: 182-4
76. Maezawa Y, Yamauchi M, Toda G. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to alcoholic liver cirrhosis. Am J Gastroenterol 1994; 89: 561-5
77. Kharasch ED, Thummel KE, Mautz D, et al. Clinical enflurane metabolism by cytochrome P4502E1. Clin Pharmacol Ther 1994; 55: 434-40
78. Pohl LR, Kenna JG, Satoh H, et al. Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989; 20: 203-17
79. Pohl LR. Drug-induced allergic hepatitis. Semin Liver Dis 1990; 10: 305-15
80. National Halothane Study. Summary of the national halothane study. JAMA 1966; 197: 121-34
81. Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993; 58: 133-55
82. Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988; 8: 1635-41
83. Park BK, Kitteringham NR. Effects of fluorine substitution on drug-metabolism: pharmacological and toxicological implications. Drug Metab Rev 1994; 26: 605-43
84. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalysing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyfluorane. Anesthesiology 1993; 79: 795-807
85. Mazze RI, Cousins MJ. Renal toxicity of anaesthetics: with specific reference to the nephrotoxicity of methoxyflurane. Can Anaesth Soc J 1973; 20: 64-80
86. Roman RJ, Carter JR, North WC, et al. Renal tubular site of action of fluoride in Fischer 344 rats. Anesthesiology 1977; 46: 260-4
87. Mazze RI, Cousins MJ, Barr GA. Renal effects and metabolism of isoflurane in man. Anesthesiology 1974; 40: 536-42
88. Mazze RI, Calverley RK, Smith NT. Inorganic fluoride nephrotoxicity: prolonged enflurane and halothane anaesthesia in volunteers. Anesthesiology 1977; 46: 265-71
89. Eger EI, Smuckler EA, Ferrell LD, et al. Is enflurane hepatotoxic? Anesth Analg 1986; 65: 21-30
90. Frink EJ. The hepatic-effects of sevoflurane. Anesth Analg 1995; 81: S46-50
91. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995; 82: 689-99
92. Pirmohamed M, Kitteringham NR, Breckenridge AM, et al. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem Pharmacol 1992; 44: 2307-14
93. Crill WE. Drugs 5 years later: carbamazepine. Ann Intern Med 1973; 79: 844-7
94. Shear NH, Spielberg SP, Cannon M, et al. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment. J Clin Invest 1988; 82: 1826-32
95. Pirmohamed M, Kitteringham NR, Guenthner TM, et al. Investigation into the formation of cytotoxic, protein reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 1992; 43: 1675-82
96. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32: 741-9
97. Tybring G, von Bahr C, Bertilsson L, et al. Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab Dispos 1981; 9: 561-4
98. Kroetz DL, Kerr BM, McFarland LV, et al. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther 1993; 53: 306-15
99. Madden S, Maggs JL, Kitteringham NR, et al. Bioactivation of carbamazepine in the rat in vivo. Br J Clin Pharmacol 1996; 41: 464P
100. Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos 1982; 10: 1-10
101. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10.11 - epoxide formation. Biochem Pharmacol 1994; 47: 1969-79
102. Bernus I, Dickinson RG, Hooper WD, et al. Early-stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 1994; 47: 355-60
103. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142-53
104. Green VJ, Pirmohamed M, Kitteringham NR, et al. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995; 50: 1353-9
105. Lillibridge JH, Amore BM, Slattery JT, et al. Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 1996; 24: 509-14
106. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990; 10: 267-78
107. Pumford NR, Martin BM, Hinson JA. A metabolite of acetaminophen covalently binds to the 56kDa selenium binding protein. Biochem Biophys Res Commun 1992; 182: 1348-53
108. Raucy JL, Lasker JM, Lieber CS, et al. Acetaminophen activation by human liver cytochromes P-450IIE1 and P-450IA2. Arch Biochem Biophys 1989; 271: 270-83
109. Thummel KE, Lee CA, Kunze KL, et al. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone inline by human CYP3A4. Biochem Pharmacol 1993; 45: 1563-9
110. Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 1986; 104: 399-404
111. Bray GP, Harrison PM, O'Grady JG, et al. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol 1992; 11: 265-70
112. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22: 767-73
113. Grossman SJ, Jollow DJ. Role of dapsone hydroxylamine in dapsone induced hemolytic anemia. J Pharmacol Exp Ther 1988; 244: 118-25
114. Zuidema J, Hilbers-Moddermann ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299-315
115. Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 1989; 28: 389-95
116. Uetrecht J, Zahid N, Shear NH, et al. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988; 245: 274-9
117. Kramer PA, Glader BE, Li TK. Mechanism of methaemoglobin formation by diphenylsulfones. Effect of 4-amino-4′-hydroxyaminodiphenylsulfone and other p-substituted derivatives. Biochem Pharmacol 1972; 21: 1265-74
118. Park BK, Pirmohamed M, Tingle MD, et al. Bioactivation and bioinactivation of drugs and drug metabolites: relevance to adverse drug reactions. Toxicol In Vitro 1994; 8: 613-21
119. Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995; 40: 531-9
120. Fleming CM, Branch RA, Wilkinson GR, et al. Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 1992; 41: 975-80
121. Mitra AK, Thummel KE, Kalhorn TF, et al. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58: 556-66
122. Coleman MD, Rhodes LE, Scott AK, et al. The use of cimetidine to reduce dose-dependent methaemoglobinaemia in dermatitis hepertiformis patients. Br J Clin Pharmacol 1992; 34: 244-9
123. Gometz JL, Dupont A, Casen L, et al. Incidence of liver toxicity associated with the use of flutamide in prostatic cancer patients. Am J Med 1992; 92: 465-70
124. Corkery JC, Bihrle I, McCalfrey JA, et al. Flutamide-related fulminant hepatic failure. J Clin Gastroenterol 1991; 13: 364
125. Hart W, Stricker BHC. Flutamide and hepatitis. Ann Intern Med 1989; 110: 943-4
126. Moller S, Iverson P, Franzman MB. Flutamide-induced liver failure. J Hepatol 1990; 10: 346-9
127. Berson A, Wolf C, Chacaty C, et al. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450. including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 1993; 265: 366-72
128. Burchell B, Nebert DW, Nelson DR, et al. The UDP glucuronosyl-transferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991; 10: 487-94
129. Tephly TR, Townsend M, Green MD. UDP-glucuronosyl-transferases in the metabolic disposition of xenobiotics. Drug Metab Rev 1989; 20: 689-95
130. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as detoxification mechanism. Drug Metab Rev 1992; 24: 5-47
131. Kroemer HK, Klotz U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992; 23: 292-310
132. Smith PC, McDonagh AF, Benet LZ. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest 1986; 77: 934-9
133. Pumford NR, Myers TG, Davila JC, et al. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem Res Toxicol 1993; 6: 147-50
134. Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac. Hepatology 1995; 22: 213-22
135. Banks AT, Zimmerman HJ, Ishak KG, et al. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-7
136. Boyer TD. The glutathione-S-transferases: an update. Hepatology 1989; 9: 486-96
137. van Bladeren PJ. Formation of toxic metabolites from drugs and other xenobiotics by glutathione conjugation. Trends Pharmacol Sci 1988; 9: 295-9
138. Guenthner TM, Kuk J, Nguyen M, et al. Epoxide hydrolases: immunochemical detection in human tissues. In: Jeffrey EH, editors. Human drug metabolism: from molecular biology to man. Boca Raton: CRC Press, 1993: 65-80
139. Skoda RC, Demierre A, McBride OW, et al. Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence. complementary DNA-directed expression in COS-1 cells, and chromosomal localization. J Biol Chem 1988; 263: 1549-54
140. Uetrecht JP. Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes. Trends Pharmacol Sci 1989; 10: 463-7
141. Uetrecht JP. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24: 299-366
142. Fischer V, Haar JA, Greiner L, et al. Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol Pharmacol 1991; 40: 846-53
143. Maggs JL, Williams D, Pirmohamed M, et al. The metabolic formation of reactive intermediates from clozapine: a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 1995; 275: 1463-75
144. Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to cells. J Pharmacol Exp Ther 1995; 275: 1476-83
145. Furst SM, Uetrecht JP. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol 1993; 45: 1267-75
146. Kling TE, Thompson DC, Foureman GL, et al. Prostaglandin-h synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990; 30: 1-45
147. Moldeus P, Rahimtula A. Metabolism of paracetamol to a glutathione conjugale catalysed by prostaglandin synthetase. Biochem Biophys Res Commun 1980; 96: 469-75
148. Potter DW, Hinson JA. The 1-electron and 2-electron oxidation of acetaminophen catalyzed by prostaglandin-H synthase. J Biol Chem 1987; 262: 974-80
149. West PR, Harman LS, Josephy PD, et al. Acetaminophen: enzymatic formation of a transient phenoxyl free-radical. Biochem Pharmacol 1984; 33: 2933-6
150. Boyd JA, Eling TE. Prostaglandin endoperoxide synthetase-dependent co-oxidation of acetaminophen to intermediates which covalently bind in vitro to rabbit renal medullary microsomes. J Pharmacol Exp Ther 1981; 219: 659-64
151. O'Neill PM, Harrison AC, Storr RC, et al. The effect of fluorine substitution on the metabolism and antimalarial activity of amodiaquine. J Med Chem 1994; 37: 1362-70
152. Tingle MD, Jewell H, Maggs JL, et al. The bioactivation of amodiaquine by human polymorphonuclear leukocytes in-vitro: chemical mechanisms and the effects of fluorine substitution. Biochem Pharmacol 1995; 50: 1113-9